Impact of parenteral n-3 fatty acids on experimental acute colitis


Department of Gastroenterology, Laboratory of Metabolism and Nutrition in Surgery, University of São Paulo Medical School, São Paulo, Brazil

The present study was undertaken to investigate the effects of parenteral lipid emulsions (LE) enriched with n-3 fatty acids (n-3 FA) in experimental acute colitis. Seventy-four adult male Wistar rats were randomized into six groups, five of which had acetic acid-induced colitis. The animals received a fat-free diet and water ad libitum in individual metabolic cages. By a central venous catheter, saline was infused (0.5 ml/h) into the control groups CS (without colitis) and CC (with colitis), while the test groups received specific LE for 7 days. The $n-3/n-6$ FA ratio and the lipidic compositions regarding long chain (LCT) and medium chain (MCT) triglycerides were: group L – 1:7:7 (LCT, n = 12), M – 1:7:0 (MCT and LCT, n = 12), LW-3 – 1:4:5 (LCT plus n-3 FA, n = 12) and MW-3 – 1:3:0 (MCT and LCT plus n-3 FA, n = 13). The frequency of diarrhea, oral intake/body weight ratio, intestinal alterations, macrophage cellularity were evaluated and colonic concentrations of leukotrienes (LTB$_4$, LTC$_4$), prostaglandins (PGE$_2$) and thromboxanes (TXB$_2$) were measured. Groups M, MW-3 and LW-3 had less diarrhea than the CC group ($P<0.05$). Average oral intake/body weight ratio in MW-3 animals was comparable to the CS and better than the CC group. n-3 FA treated rats (LW-3 and MW-3) presented less intestinal inflammatory alterations than CC rats. Mucosal ulcer formation in MW-3 group did not differ from CS rats. M and MW-3 rats had less macrophages in the colon than the CC group. Compared with CC group, lower concentrations of LTB$_4$ in the CS, LW-3 and MW-3 groups; of PGE$_2$ in the CS, M and MW-3 groups; and of TXB$_2$ in the CS and MW-3 groups were found. Mean concentrations of LTC$_4$ did not differ among the groups. Thus, a LCT-containing LE with a low n-3–n-6 ratio does not modify inflammatory colitis manifestations; LE with a high n-3–n-6 ratio reduces diarrhea, preserves oral intake–weight ratio, attenuates morphological consequences and decreases colonic concentrations of inflammatory mediators; MCT/LCT-containing LE with 1:3 n-3–n-6 ratio exerts the most profound beneficial impact on the inflammatory response.

**Inflammatory bowel diseases: Ulcerative colitis: Lipids: n-3 Polyunsaturated fatty acids: Inflammatory mediators: Fat emulsion**

Introduction

Inflammatory bowel diseases (IBD) are afflictions of unknown etiology which involve genetic, environmental and immunological factors in the pathogenesis (Sartor, 1997; Rutgeerts, 1998).

Medical management of IBD is based on anti-inflammatory and immunosuppressive drugs (Teixeira et al. 1993; Habr-Gama, 1994). Nutritional therapy might be beneficial in different phases of the disease in order to affect nutritional status or to control active disease. Therefore, a suitable nutritional formula should include nutrients that provide energy and also modulate inflammation, while exerting minimum antigenic stimulus (Carpentier et al. 1997; Campos et al. 1998).

The nutritional efficacy of lipid emulsions (LE) is dependent on the omega-3–omega-6 fatty acid ratio ($n$-3–$n$-6 FA) as well as on the fatty acid chain length of the component triglyceride (Fürst, 1994). The potential benefits of supplemental fish oil have been emphasized in various inflammatory and immunological disorders (Morlion et al. 1997; Alexander, 1998; Fürst & Kuhn, 2000). The biochemical mode of action is thought to be due to a competition of the high amount of $n$-3 FA with arachidonic

**Abbreviations:** FO, fish oil; IBD, inflammatory bowel disease; LCT, long chain triglycerides; LE, lipid emulsions; LT, leukotrienes (LTB$_4$, LTC$_4$); MCT, medium chain triglycerides; n-3 FA, omega-3 fatty acid; n-6 FA, omega-6 fatty acid; PG, prostaglandins (PGE$_2$); TX, thromboxanes (TXB$_2$).

* Corresponding author: Dr F. Guilherme Campos, Alameda Jau, 1477 apto 111, São Paulo (SP), CEP: 01420-002, Brazil. Fax +55 011 3081443, email fgcampos@osite.com.br
acid (n-6 family) at the site of the membrane. Indeed this action reduces the synthesis of proinflammatory leukotrienes (4-series) and thromboxanes (2-series) and favours the anti-inflammatory 5 and 3 series, respectively (Roper & Phipps, 1994; Calder, 1996).

The goal of the present study was to investigate the effects of n-3 FA enriched LE on experimental acute colitis. Clinical, histological and inflammatory alterations induced in the presence of LE with variations in the n-3–n-6 ratio and in the triglyceride-fatty acid chain length were evaluated.

Methods

Seventy-four male, adult, Wistar rats weighing 200–220 g were randomized according to rectal infusion and parenteral solutions and emulsions infused into six groups (Table 1). Ethical approval for this research was obtained by the Department of Gastroenterology (University of São Paulo Medical School, São Paulo). The animals were fed a fat-free oral diet and were housed individually in metabolic cages.

On the first day five groups of animals received a 2 ml rectal infusion of 10% acetic acid and one group (CS) received physiological saline as described by MacPherson & Pfeiffer (1978). All the animals were subsequently infused with saline for 48 h by a central venous catheter. After that, the control animals (CS and CC groups) were continuously infused parenterally with saline and the experimental groups (L, M, LW-3 and MW-3) received parenteral infusions of 10% lipid emulsions. Parenteral volumes were provided through an infusion pump at 0.5 ml/h for 7 days. At completion of the study (tenth day) the entire colon was resected for further analyses (Fig. 1).

The frequency of diarrhea was monitored and the oral intake/body weight relation was assessed. After laparotomy, intestinal alterations (bowel dilatation and thickening, mesenteric inflammation, small bowel and epiploon adhesions) were evaluated and the entire colon resected. Each alteration added one point to each rat; thus, total points varied from 0 to 5. The average of each group was then calculated and compared to the other groups.

Intestinal fragments were taken from inflamed areas usually at the left colon and submitted to histological analysis. Regarding intestinal morphology, animals were separated in two groups according to the presence or absence of microscopic ulcers.

Intestinal alterations (bowel dilatation and thickening, mesenteric inflammation, small bowel and epiploon adhesions) were evaluated and the entire colon resected. The results are shown in Tables 3 and 4 and the statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

Results

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. Regarding feces consistency, groups M (11), MW-3 (11) and LW-3 (12) had a greater number of rats without diarrhea than the CC group (5) (P<0.05). All groups of animals had an average lower oral intake–body weight ratio when compared to the CS group (137±8), except MW-3 (129±8), in which the ratio was even higher than that of the CC group (106±8) (P<0.05). Rats treated with fish oil enriched emulsions (LW-3 and MW-3) showed less intestinal inflammatory alterations (1-1 and 0-9, respectively) than the CC rats (2-7) (P<0.05). Rats infused with MCT/LCT

Macrophage cellularity was determined by immunohistochemistry using the alkaline phosphatase anti-alkaline phosphatase (APAAP) method (Noronha et al. 1995). Macrophage cellularity was divided according to scores of inflammation representing three features: number, distribution and location in relation to the basal membrane. According to these features, macrophage scores varied from 1 to 5 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.

The results are shown in Tables 3 and 4 and the corresponding statistical analysis is summarized in Table 5. According to these features, macrophage scores varied from 5 to 10 (Table 2).

Colonic concentrations of leukotrienes (LTB_4, LTC_4), prostaglandins (PGE_2) and thromboxanes (TXB_2) were determined by immune-enzymatic-assay (Pradelles et al. 1985).

Statistical analysis was made using the following methodology: Kruskal-Wallis test for oral intake/body weight ratio, inflammatory alterations and macrophage cellularity; Fisher Exact test for the frequency of diarrhea and histological analysis; Bonferroni’s test for concentrations of inflammatory mediators. Significance level was P<0.05.
plus fish oil LE (MW-3) were the only experimental group where mucosal ulcer formation assessed by histology was practically absent (ten rats) as seen in the control group (nine rats). Actually, macrophage cellularity scores were lower than in the CC group (9) only in rats infused with MCT/LCT LE alone (M group – 7.1) or enriched with fish oil (FO) (MW-3 group – 6.8) (P<0.05).

### Table 2. Colon macrophage cellularity. Scores related to number of macrophages, distribution and location

<table>
<thead>
<tr>
<th>Number</th>
<th>Distribution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low 1</td>
<td>High 2</td>
<td>Isolated 1</td>
</tr>
<tr>
<td>Final score</td>
<td>Final score</td>
<td>Final score</td>
</tr>
<tr>
<td>2 x 1 = 2</td>
<td>2 x 2 = 4</td>
<td>1 x 1 = 1</td>
</tr>
</tbody>
</table>

BM = basal membrane.

### Table 3. Results of physiological and inflammatory changes

<table>
<thead>
<tr>
<th>Variable</th>
<th>Groups</th>
<th>CS</th>
<th>CC</th>
<th>L</th>
<th>LW-3</th>
<th>M</th>
<th>MW-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feces</td>
<td>normal (n)</td>
<td>12</td>
<td>5</td>
<td>8</td>
<td>12</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Consistency</td>
<td>altered (n)</td>
<td>0</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Oral intake/</td>
<td>mean</td>
<td>137.7</td>
<td>106.8</td>
<td>104.0</td>
<td>92.6</td>
<td>104.9</td>
<td>129.8</td>
</tr>
<tr>
<td>body weight ratio</td>
<td>± 21-1</td>
<td>24.9</td>
<td>30.0</td>
<td>21.7</td>
<td>21.0</td>
<td>26.5</td>
<td></td>
</tr>
<tr>
<td>Abdominal</td>
<td>mean</td>
<td>0</td>
<td>2.7</td>
<td>2.5</td>
<td>1.1</td>
<td>2.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Alterations</td>
<td>± 0</td>
<td>1.8</td>
<td>1.9</td>
<td>1.6</td>
<td>1.4</td>
<td>1.7</td>
<td></td>
</tr>
<tr>
<td>Mucosal ulcers</td>
<td>present (n)</td>
<td>0</td>
<td>10</td>
<td>8</td>
<td>5</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Macrophage cellularity</td>
<td>mean</td>
<td>5.1</td>
<td>9.1</td>
<td>8.2</td>
<td>8.5</td>
<td>7.1</td>
<td>6.8</td>
</tr>
</tbody>
</table>

n = number. 
± = standard deviation.

### Table 4. Median values of pro-inflammatory mediators

<table>
<thead>
<tr>
<th>Eicosanoid</th>
<th>CS</th>
<th>CC</th>
<th>L</th>
<th>LW-3</th>
<th>M</th>
<th>MW-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTB4 (ng/g)</td>
<td>58.3</td>
<td>341.4</td>
<td>192.3</td>
<td>41.4</td>
<td>171.5</td>
<td>83.9</td>
</tr>
<tr>
<td>PGE2 (pg/g)</td>
<td>1626.8</td>
<td>7660.7</td>
<td>2535.7</td>
<td>3138.5</td>
<td>2148.6</td>
<td>2235.8</td>
</tr>
<tr>
<td>TXB2 (pg/g)</td>
<td>807.5</td>
<td>6416.4</td>
<td>1578.7</td>
<td>902.5</td>
<td>940.8</td>
<td>709.4</td>
</tr>
</tbody>
</table>

LT = leukotriene; PG = prostaglandin; TX = thromboxane. 
± = standard deviation.

### Table 5. Results of statistical analysis and P-values of physiological variables, inflammatory changes and eicosanoids

<table>
<thead>
<tr>
<th>Variables</th>
<th>Statistical analysis</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal feces</td>
<td>CC &lt; LW – 3; M; MW-3</td>
<td>P=0.0002a</td>
</tr>
<tr>
<td>Oral intake/body weight relation</td>
<td>CC &lt; MW – 3</td>
<td>P=0.000001b</td>
</tr>
<tr>
<td>Inflammatory alterations</td>
<td>CC &gt; CS, LW-3, MW-3</td>
<td>P=0.0009c</td>
</tr>
<tr>
<td>Macrophage cellularity</td>
<td>CC &gt; CS, M, MW-3</td>
<td>P=0.0003d</td>
</tr>
<tr>
<td>Ulcers on histology</td>
<td>CC &gt; CS, MW-3</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>Leukotriene B4</td>
<td>CC &gt; CS, LW-3, MW-3</td>
<td>P=0.0017e</td>
</tr>
<tr>
<td>Leukotriene C4</td>
<td>No difference</td>
<td>P=0.3375f</td>
</tr>
<tr>
<td>Prostaglandin E2</td>
<td>CC &gt; CS, M, MW-3</td>
<td>P=0.0049g</td>
</tr>
<tr>
<td>Thromboxane B2</td>
<td>CC &gt; CS, MW-3</td>
<td>P=0.0138h</td>
</tr>
</tbody>
</table>

aFisher Exact test; bKruskal-Wallis test; cBonferroni’s test.
The median colonic concentrations of eicosanoids indicated significantly lower concentrations of LTB₄ in n-3FA supplemented groups (LW-3 and MW-3) when compared to the CC group (41 and 84 v. n in inflammatory effect on the mucosa, while supplemental observation supports the potential clinical benefits of this formula in acute colitis. This result was not found when comparing the LW-3 and CC groups. This could be attributable to the reduced (50 %) concentrations of LCT in M and MW-3 LE. We also observed a reduction in the concentration of TXB₂ in MW-3 treated rats, similar to the observations of Campbell et al. (1997); Yeh et al. (1997) with enteral or parenteral n-3 FA, respectively.

Administration of oral n-3 FA in IBD has presented contradictory results, either showing low effectiveness (Aslan & Triadafilopoulos, 1992; Greenfield et al. 1993; Loeschke et al. 1996; Lorenz-Meyer et al. 1996) or exhibiting some benefits like histological improvement and reduction in eicosanoid production (Guarrner et al. 1992; Inui et al. 1996; Nieto et al. 1998). On the other hand, studies using parenteral provision of n-3 FA suggest that the venous route is more effective in the modulation of cytokine and eicosanoid patterns and thereby in the management of acute inflammation, even with short-term treatment (Grimminger et al. 1993b; Morlion et al. 1997; Tashiro et al. 1998; Hayashi et al. 1999). Particularly in IBD, favourable results have been reported in clinical (Ikehata et al. 1992; Grimminger et al. 1993a) and experimental studies (Inui et al. 1996) by using parenteral supplementation of n-3 FA.

An increased n-3–n-6 FA ratio might be associated with certain pharmacological advantages and less immunosuppressive effects (Fürst, 1994; Grimm et al. 1994, 1995;

Discussion

Experimental models of colitis have been widely used to study the pathogenesis and therapy of IBD (Sartor, 1997). The intracolonic administration of acetic acid is a simple, low cost and reproducible method used in small animals (MacPherson & Pfeiffer, 1978; Moraes, 1987, 1989), and the resulting inflammation shares similarities with human IBD regarding histological aspects and eicosanoid metabolism (Sharon & Stenson, 1985). In the present study, differences in almost all variables were observed between the CC and CS groups, indicating that the model was effective in our hands.

Diarrhea, reduced oral intake and weight loss are common symptoms in IBD patients. Interestingly, in the present study LCT containing LE (L group) showed no anti-inflammatory effect on the mucosa, while supplemental n-3 FA ameliorated intestinal function (MW-3 group). The effect of n-3 FA in reducing IBD-associated symptoms is due to a reduced intestinal inflammatory response (less secretion, improved mucosal permeability, greater absorption) (McCall et al. 1989; Salomon et al. 1990; Grimminger et al. 1993a; Almallah et al. 1998) and improved colonic blood perfusion (Pomposelli et al. 1990; Pscheidl et al. 1992; Pscheidl & Böke-Pröls, 1997).

Anorexia is considered a feature of the metabolic response to pro-inflammatory cytokine elevation in rat colitis (Grimble, 1998). In this study, animals infused with MCT/LCT plus FO emulsion had a better oral intake–weight ratio than the other groups. It is recognized that while n-3 FA reduce the inflammatory response, n-6 FA have the opposite effect (Alexander, 1998). Furthermore, it was claimed that MCT promotes protein economy since the medium chain fatty acids are readily oxidized, so sparing amino acids from being used as energy (Jiang et al. 1993). The data from the present study suggest that n-3 FA supplementation in MCT/LCT LE preserved the oral intake–weight ratio because of reduced anorexia and protein catabolism. This experimental data emphasizes the potential clinical benefits of this formula in acute colitis.

In our investigation, less abdominal and intestinal inflammatory changes were found in FO treated groups at laparotomy, with reduced incidence of macroscopic alterations reflecting a lower degree of bowel injury. This observation supports the potential clinical benefit of supplemental n-3 FA in colitis. Our results are in good agreement with those obtained in trinitro benzoic sulfonyl acid (TNBS)-induced colitis in rats treated with n-3 FA supplemented total parenteral nutrition (Inui et al. 1996).

Rats receiving MCT/LCT plus n-3 FA (MW-3 group) exhibited greater protection against the development of severe morphological damage. Histological improvement (reduced ulcer formation, preservation of mucosal barrier and faster recovery after injury) has also been demonstrated in other experimental (Marotta et al. 1995; Shoda et al. 1995) and clinical settings (Stenson et al. 1992) by using supplemental n-3 FA.

Intestinal macrophages have an important role in mucosal inflammation (Rogler et al. 1997). In the present study, the average scores of inflammation in the M and MW-3 groups were less than in the colitis control group (CC). This might indicate that the use of MCT/LCT emulsions is associated with reduced inflammation and macrophage recruitment. A growing body of evidence suggests that n-6 FA containing LCT emulsions are immunosuppressive and thus exert deleterious effects on immune cells (Cukier et al. 1997; Gelas et al. 1998), thereby affecting cytokine and eicosanoid synthesis and resulting in increased injury (Ulrich et al. 1996). Indeed, the greater proportion of n-3 FA (MW-3 group) in the present study might modify the profile of inflammatory mediator synthesis, stimulate cell defense mechanisms and result in less chemotaxis and cell adherence (Lee et al. 1985; Morlion et al. 1997; Grimm et al. 1998; Fürst & Kuhn, 2000).

In the present work, mucosal LTB₄ concentrations were reduced in the n-3 FA treated groups when compared to the control group with colitis (CC). This may be a consequence of the known competition between eicosapentaenoic and arachidonic acids. Similarly, other studies showed that supplemental n-3 FA reduce levels of LTB₄ in IBD patients (Stenson et al. 1992) and in experimental colitis (Guarrner et al. 1992; Inui et al. 1996; Nieto et al. 1998).

M and MW-3 were the only groups that had lower PGE₂ concentrations compared to the CC group. The same result was not found when comparing the LW-3 and CC groups. This could be attributable to the reduced (50 %) concentrations of LCT in M and MW-3 LE. We also observed a reduction in the concentration of TXB₂ in MW-3 treated rats, similar to the observations of Campbell et al. (1997); Yeh et al. (1997) with enteral or parenteral n-3 FA, respectively.
Hayashi et al. (1999). On the basis of the effect on the 
LTC₄/LTC₄ ratio, it was proposed that the n-3–n-6 ratio should be 
between 1: 2 and 1: 4 (Morlion et al. 1997; Grimm 
et al. 1998).

In the present study the ratios of n-3–n-6 FA in the LE 
were 1:7:7 (group L), 1: 7:0 (M), 1:4:5 (LW-3) and 1: 3:0 
(MW-3). Therefore it is not surprising that only the n-3 FA 
enriched emulsions revealed effective modulation of 
inflammation in this model of acute colitis.

The present results together with the available literature 
suggest that the parenteral provision of n-3 FA is a 
beneficial therapeutic approach for acute intestinal inflam-
mation. The management of IBD patients by using 
immunomodulatory nutrients should be further scrutinized 
in controlled studies in order to evaluate if triglyceride 
composition (i.e. fatty acid chain length), duration of 
treatment and the use of different n-3–n-6 FA ratios could 
aff ect clinical results and immune status.

Conclusions

An LCT-containing lipid emulsion with low n-3–n-6 FA 
ratio did not affect manifestations of colitis. The use of 
enriched emulsions with high n-3–n-6 FA ratio reduced diarrhea, 
decreased inflammation changes, attenuated morphological 
injury and decreased concentrations of eicosanoids. The most 
profound benefi cial impact was observed with 
MCT/LCT containing lipid emulsion where the n-3–n-6 
FA ratio was 1:3.

References

Nutrition 14, 627–633.

Almallah YZ, Richardson S, O’Hanrahan T, Mowat NA, Brunt 
procto-colitis, natural cytotoxicity and essential fatty acids. 
American Journal of Gastroenterology 93, 804–809.

Aslan AMD & Triadafilopoulos GMD (1992) Fish oil fatty acid 
supplementation in acute ulcerative colitis: a double-blind, 
placebo-controlled, crossover study. American Journal of 
Gastroenterology 87, 432–437.

Calder PC (1996) Immunomodulatory and the anti-inflammatory 
effects of n-3 polysaturated fatty acids. Proceedings of 
Nutritional Society 55, 737–747.

Campbell JM, Fahey GC, Lichtensteiger CA, Demichele SJ & 
Garleb KA (1997) An enteral formula containing fish oil, 
indigestible oligosaccharides, gum arabic and antioxidants 
affects plasma and colonic phospholipid fatty acid and 
prostaglandin profiles in pigs. Journal of Nutrition 127, 
137–145.

Campos FG, Waitzberg DL, Plopper C, Terra RM & Habr-Gama A 

Carpentier YA, Simoens C, Siderova V, Vanweyenberg V, 
Eggerickx DA & Deckelbaum RJ (1997) Recent developments in 
lipid emulsions: relevance to intensive care. Nutrition 13, 
73–78.

Cukier C, Waitzberg DL, Soares SR, Loguollo AF, Bacchi CE, 
Travassos VH, Saldiva PH, Torrinhias RS & Oliveira TS (1997) 
Effect of glucidic and fat total parenteral nutrition on 
macrophage phagocytosis in rats. Revista Hospital Clinicas 
Faculdade Medicina São Paulo 52, 239–245.

Fürst P (1994) New parenteral substrates in clinical nutrition Part 
II. New substrates in lipid nutrition. European Journal Clinical 
Nutrition 48, 681–691.

Fürst P & Kuhn KS (2000) Fish oil emulsions: what benefits can 

medium- and long- chain triglycerides on lymphocytes 
subpopulations and functions in patients with acquired 
immunodeficiency syndrome: a prospective study. Journal of 

Greenfield SM, Green AT, Teare JP, Jenkins AP, Punchard NA, 
Ainley CC & Thompson RP (1993) A randomized controlled 
study of evening primrose oil and fish oil in ulcerative colitis. 
Alimentary Pharmacology Therapy 7, 159–166.

Nutrition 14, 634–640.

Grimm H, Tibell A, Norrlin B, Blecher C, Wilker S & 
Schwemmle K (1994) Immunoregulation by parenteral lipids: 
Impact of the n-3 to n-6 fatty acid ratio. Journal of 
Parenteral and Enteral Nutrition 18, 417–442.

Grimm H, Tibell A, Norrlin B, Schott J, Bohle RM, Papavassilis 
C, Fuhrer D, Mayer K & Grimminger F (1995) Immunosup-
pressive effect of parenteral fat emulsions in defined 
immunostimulation. Infusionstherapie und Transfusionsmedizin 

immono-neutral lipid emulsion for optimal postoperative 
management of intensive care patients. Langenbecks Archive 

Grimminger F, Fuhrer D, Papavassilis C, Schlotzer E, Mayer K, 
Heuer K, Kiss L, Walmrath D, Kramer HJ & Seeger W (1993a) 
Influence of intravenous n-3 lipid supplementation on fatty acids 
profiles and lipid mediator generation in patients with severe 
ulcerative colitis. European Journal of Clinical Investigation 
23, 706–715.

Grimminger F, Mayser P, Papavassilis C, Thomas M, Schlotzer E, 
Heuer K, Fuhrer D, Walmrath D, Schill WB & Seeger W 
(1993b) A double-blind, randomized, placebo-controlled trial of 
n-3 fatty acid based lipid infusion in acute, extended guttate 

manipulation in experimental inflammatory bowel disease. 
Agents Actions, Special Conference Issue.


Hayashi N, Tashiho T, Yamamori H, Kramer HJ & Seeger W (1993a) 
A comparison of medium-chain and long-chain triglycerides in 
surgical patients. Proceedings of 
Nutritional Society 55, 737–747.

Ikehata A, Hwatushi N, Kinouchi Y, Yamazaki H, Kumagai Y, Ito 
K, Kayaba Y & Toyota T (1992) Effect of intravenously infused 
eicosapentaenoic acid on the leukotriene generation in patients 
with active Crohn’s disease. American Journal of Clinical 
Nutrition 56, 938–942.

The effect of alpha-linolenic acid-rich emulsion on fatty acid 
metabolism and leukotriene generation of the colon in a rat 
model with inflammatory bowel disease. Annals of Nutrition & 
Metabolism 40, 175–182.

A comparison of medium-chain and long-chain triglycerides in 

Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, 
only delay early relapse of ulcerative colitis in remission. 
Digestive Disease Sciences 41, 2087–2094.


